Patents Assigned to Vision Pharmaceuticals
-
Patent number: 10479805Abstract: A beta-lactamase inhibitor having a formula (I). Also provided is a method of using the beta-lactamase inhibitor for prevention or treatment of diseases.Type: GrantFiled: October 19, 2018Date of Patent: November 19, 2019Assignee: WUHAN VISION PHARMACEUTICAL TECHNOLOGY CO., LTD.Inventors: Shiping Wu, Hongyu Xu, Xiangdong Hu
-
Patent number: 9580395Abstract: A dual thyrointegrin antagonist and a method for treating an angiogenesis-mediated disorder and/or a hyperthyroidism disorders by introducing the dual thyrointegrin antagonist into animals (e.g., mammals, human beings). The dual thyrointegrin antagonist includes a chemical structure having a thyroid hormone antagonist and ?v?3 integrin antagonist in the same molecule.Type: GrantFiled: October 9, 2014Date of Patent: February 28, 2017Assignee: VASCULAR VISION PHARMACEUTICAL COMPANYInventor: Shaker A. Mousa
-
Patent number: 8859539Abstract: A dual thyrointegrin antagonist and a method for treating an angiogenesis-mediated disorder and/or a hyperthyroidism disorders by introducing the dual thyrointegrin antagonist into animals (e.g., mammals, human beings). The dual thyrointegrin antagonist includes a chemical structure having a thyroid hormone antagonist and ?v?3 integrin antagonist in the same molecule.Type: GrantFiled: November 1, 2010Date of Patent: October 14, 2014Assignee: Vascular Vision Pharmaceutical CompanyInventor: Shaker A. Mousa
-
Patent number: 8607989Abstract: A filter and a method of forming a suture structure. The filter includes layered structure(s) interior to the filter. Each layered structure includes a carbon structure comprising carbon and a coating on a surface of the carbon structure. Each layered structure may further include a heparin layer that includes heparin and is on the coating. The coating of the filter includes cellulose, PMMA, PEMA, or PHEMA. The carbon structure may include an activated charcoal layer or carbon nanotube(s). The layered structure is configured to remove a contaminant flowing through the filter. The method of forming the suture structure includes forming a film on a suture that has been previously formed on a mammal. The film includes both a coating on the suture and a heparin layer that includes heparin and is on the coating. The coating of the suture structure includes cellulose, PMMA, PEMA, or PHEMA.Type: GrantFiled: June 15, 2010Date of Patent: December 17, 2013Assignee: Vascular Vision Pharmaceutical Co.Inventors: Shaker A. Mousa, Robert J. Linhardt
-
Patent number: 8314078Abstract: A silver nanocomposite, a formation method for forming the silver nanocomposite, and an application method utilizing the silver nanocomposite. The silver nanocomposite includes a silver nanoparticle conjugated to a glycosaminoglycan (GAG) or glucose. The formation method includes chemically reacting silver nitrate with a reducing agent to form a silver nanoparticle conjugated to the reducing agent of a GAG or glucose. The application method may include topically applying the silver nanocomposite to a wound or burn as an anti-microbial with respect to an antibiotic-resistant genotype in the wound or burn, wherein the silver nanocomposite topically applied includes the silver nanoparticle conjugated to the GAG of 2,6-diaminopyridinyl heparin (DAPHP) or hyaluronan (HA). The application method may include applying the silver nanocomposite as a coating to plastic, a catheter, or a surgical tool, wherein the silver nanocomposite applied as the coating includes the silver nanoparticle conjugated to the GAG of DAPHP.Type: GrantFiled: June 9, 2010Date of Patent: November 20, 2012Assignee: Vascular Vision Pharmaceutical Co.Inventors: Shaker A. Mousa, Robert J. Linhardt
-
Publication number: 20110105482Abstract: A dual thyrointegrin antagonist and a method for treating an angiogenesis-mediated disorder and/or a hyperthyroidism disorders by introducing the dual thyrointegrin antagonist into animals (e.g., mammals, human beings). The dual thyrointegrin antagonist includes a chemical structure having a thyroid hormone antagonist and ?v?3 integrin antagonist in the same molecule.Type: ApplicationFiled: November 1, 2010Publication date: May 5, 2011Applicant: VASCULAR VISION PHARMACEUTICAL COMPANYInventor: Shaker A. Mousa
-
Publication number: 20100317617Abstract: A silver nanocomposite, a formation method for forming the silver nanocomposite, and an application method utilizing the silver nanocomposite. The silver nanocomposite includes a silver nanoparticle conjugated to a glycosaminoglycan (GAG) or glucose. The formation method includes chemically reacting silver nitrate with a reducing agent to form a silver nanoparticle conjugated to the reducing agent of a GAG or glucose. The application method may include topically applying the silver nanocomposite to a wound or burn as an anti-microbial with respect to an antibiotic-resistant genotype in the wound or burn, wherein the silver nanocomposite topically applied includes the silver nanoparticle conjugated to the GAG of 2,6-diaminopyridinyl heparin (DAPHP) or hyaluronan (HA). The application method may include applying the silver nanocomposite as a coating to plastic, a catheter, or a surgical tool, wherein the silver nanocomposite applied as the coating includes the silver nanoparticle conjugated to the GAG of DAPHP.Type: ApplicationFiled: June 9, 2010Publication date: December 16, 2010Applicant: VASCULAR VISION PHARMACEUTICAL CO.Inventors: Shaker A. Mousa, Robert Linhardt
-
Publication number: 20100316694Abstract: A filter and a method of forming a suture structure. The filter includes layered structure(s) interior to the filter. Each layered structure includes a carbon structure comprising carbon and a coating on a surface of the carbon structure. Each layered structure may further include a heparin layer that includes heparin and is on the coating. The coating of the filter includes cellulose, PMMA, PEMA, or PHEMA. The carbon structure may include an activated charcoal layer or carbon nanotube(s). The layered structure is configured to remove a contaminant flowing through the filter. The method of forming the suture structure includes forming a film on a suture that has been previously formed on a mammal. The film includes both a coating on the suture and a heparin layer that includes heparin and is on the coating. The coating of the suture structure includes cellulose, PMMA, PEMA, or PHEMA.Type: ApplicationFiled: June 15, 2010Publication date: December 16, 2010Applicant: VASCULAR VISION PHARMACEUTICAL CO.Inventors: Shaker A. Mousa, Robert Linhardt
-
Publication number: 20020193876Abstract: Intraocular lenses include a lens body sized and adapted for placement in a mammalian eye and having a plurality of different optical powers, and a movement assembly joined to the lens body and adapted to cooperate with the mammalian eye to effect accommodating movement of the lens body in the eye. Such intraocular lenses provide enhanced accommodation relative to the accommodation attainable using a single optical power IOL adapted for accommodating movement.Type: ApplicationFiled: August 20, 2002Publication date: December 19, 2002Applicant: Vision Pharmaceuticals L.P.Inventors: Alan J. Lang, Valdemar Portney, Stephen W. Laguette
-
Publication number: 20010012964Abstract: Intraocular lenses include a lens body sized and adapted for placement in a mammalian eye and having a plurality of different optical powers, and a movement assembly joined to the lens body and adapted to cooperate with the mammalian eye to effect accommodating movement of the lens body in the eye. Such intraocular lenses provide enhanced accommodation relative to the accommodation attainable using a single optical power IOL adapted for accommodating movement.Type: ApplicationFiled: March 30, 2001Publication date: August 9, 2001Applicant: Vision Pharmaceuticals L.P.Inventors: Alan J. Lang, Valdemar Portney, Stephen W. Laguette
-
Patent number: 5980863Abstract: An MRI contrast medium of improved safety and efficacy is disclosed. The composition includes a source of calcium ions and a source of manganese ions in a ratio of from 2:1 to 40:1 in a vehicle suitable for parenteral administration. A method of enhancing an MRI signal in a mammalian tissue with the foregoing composition is also provided.Type: GrantFiled: November 2, 1998Date of Patent: November 9, 1999Assignee: Eagle Vision Pharmaceutical CorporationInventors: Phillip P. Harnish, Peter R. Seoane, Adele R. Vessey
-
Patent number: 5032392Abstract: An aqueous ophthalmic preparation is described for the treatment of dry and/or irritated eyes. The preparation is comprised of retinol and/or derivatives or precursors thereof, solubilized in water. Certain non-ionic surfactants and propylmethylcellulose are disclosed as solubilizing agents, with propylmethylcellulose also acting as a mucin-like constituent. The vitamin-containing preparation also contains (1) free radical scavenging compounds and (2) compounds capable, in solution, of chelating multivalent metal cations present in human and/or animal external eye tissue or tear film. The preferred free radical scavenger is mannitol. The preferred chelating agent is EDTA, present in minimal quantities for chelating certain catalytically active metallic ions present at or near the surface of the eye. Also described are tonicity adjusting compositions and an ophthalmic solution buffering system comprising citric acid and citrates.Type: GrantFiled: September 4, 1986Date of Patent: July 16, 1991Assignee: Vision PharmaceuticalsInventor: Shambhu D. Varma
-
Patent number: D921921Type: GrantFiled: January 17, 2020Date of Patent: June 8, 2021Assignee: New Vision Pharmaceuticals LLCInventor: Raimundo Jose Santamarta